Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
about
Survivin: a unique target for tumor therapyTrial Watch: Peptide-based anticancer vaccines.Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft ModelsIdentification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine
P2860
Q26747332-CDA35B20-2E89-480A-875E-7B6E96D76C0DQ34483345-4DD2575A-FDAA-4ED0-83E1-BC343D4D89BCQ34962445-35CC016C-B68E-4DCA-95D6-1E845323934EQ35694238-CF234E36-3DC3-4E82-8750-3A63B24D7D4EQ35832185-5516BF0B-A78B-4AEB-9CC1-2DAEA08C03A5Q50097295-13AD4612-8171-4C3D-AF42-32F8901CDB24Q51758973-78AAD517-69BC-4C89-9653-965B07E487CBQ56524291-C7FF2992-A48D-4A90-BEEA-65E3B70FDF06
P2860
Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Potential survival benefit of ...... from phase I clinical trials.
@en
Potential survival benefit of ...... from phase I clinical trials.
@nl
type
label
Potential survival benefit of ...... from phase I clinical trials.
@en
Potential survival benefit of ...... from phase I clinical trials.
@nl
prefLabel
Potential survival benefit of ...... from phase I clinical trials.
@en
Potential survival benefit of ...... from phase I clinical trials.
@nl
P2093
P2860
P356
P1476
Potential survival benefit of ...... from phase I clinical trials.
@en
P2093
Akari Takahashi-Takaya
Hiroshi Kitamura
Naoya Masumori
Noriyuki Sato
Ryuta Inoue
Sachiyo Kawami
Sachiyo Nishida
Taiji Tsukamoto
Toshiaki Tanaka
Toshihiko Torigoe
P2860
P304
P356
10.1155/2013/262967
P577
2013-11-20T00:00:00Z